Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan

Wenyu Ye1 Lilly Suzhou Pharmaceutical Co, Shanghai, People’s Republic of ChinaCorrespondence[email protected]

Haya Ascher-Svanum2 Eli Lilly and Company, Indianapolis, IN, USA

Jennifer A Flynn3 Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Kobe

Yuka Tanji3 Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Kobe

Michihiro Takahashi3 Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Kobe;4 Terauchi-Takahashi Psychiatric Clinic, Ashiya, Japan

Pages 13-19 | Published online: 13 Jan 2012

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

FalkaiPWobrockTLiebermanJWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophreniaWorld J Biol Psychiatry20056313219116173147
PubMed Web of Science ®Google Scholar
LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, 2nd edAm J Psychiatry2004161Suppl 215615000267
PubMed Web of Science ®Google Scholar
StahlSMAntipsychotic polypharmacy: squandering precious resources?J Clin Psychiatry2002632939411874226
PubMed Web of Science ®Google Scholar
FariesDAscher-SvanumHZhuBCorrellCKaneJAntipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychoticsBMC Psychiatry200552615921508
PubMed Web of Science ®Google Scholar
GangulyRKotzanJAMillerLSKennedyKMartinBCPrevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000J Clin Psychiatry200465101377138815491242
PubMed Web of Science ®Google Scholar
MillierASarlonEAzorinJ-MRelapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysisBMC Psychiatry2011112421314943
PubMed Web of Science ®Google Scholar
ClarkREBartelsSJMellmanTAPeacockWJRecent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorders: Implications for state mental health policySchizophr Bull2002281758412047024
PubMed Web of Science ®Google Scholar
SernyakMRosenheckRClinician’s reasons for antipsychotic coprescribingJ Clin Psychiatry200465121597160015641863
PubMed Web of Science ®Google Scholar
TappAWoodAESecrestLCombination antipsychotic therapy in clinical practicePsychiatr Serv2003541555912509667
PubMed Web of Science ®Google Scholar
CorrellCURummel-KlugeCCorvesCKaneJMLeuchtSAntipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trialsSchizophr Bull200935244345718417466
PubMed Web of Science ®Google Scholar
CorrellCUAntipsychotic polypharmacy, part 1: shotgun approach or targeted cotreatment?J Clin Psychiatry200869467467518507487
PubMed Web of Science ®Google Scholar
BarnesTREPatonCAntipsychotic polypharmacy in schizophrenia: benefits and risksCNS Drugs201125538339921476610
PubMed Web of Science ®Google Scholar
CorrellCUFredericksonAMKaneJMManuPDoes antipsychotic polypharmacy increase the risk for metabolic syndrome?Schizophr Res2007891–39110017070017
PubMed Web of Science ®Google Scholar
JerrellJMCost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medicationsSchizophr Bull200228458960512795493
PubMed Web of Science ®Google Scholar
ProcyshynRMKennedyNBTseGThompsonBAntipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institutionCan J Psychiatry200146433433911387789
PubMed Web of Science ®Google Scholar
YoshiTKurosawaMSugimuraKCurrent status of the psychopharmacological treatment of schizophrenic patients in Japan: From 2005 nationwide survey of 9 psychiatric hospitals in the psychiatric clinical pharmacy societyJpn J Clin Psychopharmacol20071017211731
Google Scholar
YoshiTUnoJNakagawaMSurvey of the prescription for psychotherapy in Japanese inpatients with schizophrenia in 2006Jpn J Clin Psychopharmacol20101315351545
Google Scholar
SimKSuAChanYClinical correlates of antipsychotic polytherapy in patients with schizophrenia in SingaporePsychiatry Clin Neurosci200458332432915149301
PubMed Web of Science ®Google Scholar
KreyenbuhlJAValensteinMMcCarthyJFGanoczyDBlowFCLongterm antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patternsPsychiatr Serv200758448917412850
PubMed Web of Science ®Google Scholar
WangPFZhaoZComparison of olanzapine versus quetiapine in the treatment of hospitalized patients with schizophreniaValue Health200363355
Web of Science ®Google Scholar
YuAPAtanasovPBen-HamadiRResource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid populationValue Health200912570871519508658
PubMed Web of Science ®Google Scholar
ZhuBAscher-SvanumHFariesDECorrellCUKaneJMCost of antipsychotic polypharmacy in the treatment of schizophreniaBMC Psychiatry200881918394168
PubMed Web of Science ®Google Scholar
NovickDAscher-SvanumSBrugnoliRAntipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European SOHO studyJ Nerv Ment Dis2011In press
Web of Science ®Google Scholar
BitterIChouJCUngvariGSPrescribing for inpatients with schizophrenia: an international multi-center comparative studyPharmacopsychiatry200336414314912905100
PubMed Web of Science ®Google Scholar
ShinfukuNTanCHPharmacotherapy for schizophrenic inpatients in East Asia: changes and challengesInt Rev Psychiatry200820546046819012132
PubMed Web of Science ®Google Scholar
HaroJMKamathSAOchoaSThe Clinical Global Impression- Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophreniaActa Psychiatr Scand Suppl2003416162312755850
PubMedGoogle Scholar
KaySROplerLAFiszbeinAPositive and Negative Syndrome Scale (PANSS) user’s manualNorth Tonawanda, NYMulti-Health Systems, Inc2000
Google Scholar
TsutsumiCUchidaHSuzukiTThe evolution of antipsychotic switch and polypharmacy in natural practice – a longitudinal perspectiveSchizophr Res20111301–3404621624824
PubMed Web of Science ®Google Scholar
EssockSMSchoolerNRStroupTSEffectiveness of switching from antipsychotic polypharmacy to monotherapyAm J Psychiatry2011168770270821536693
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date